Prognosis of pN3 Stage Gastric Cancer.
- Author:
Jung Ryun AHN
1
;
Minkyu JUNG
;
Chan KIM
;
Min Hee HONG
;
Hong Jae CHON
;
Hye Ryun KIM
;
Hei Cheul JEUNG
;
Woo Jin HYUNG
;
Sung Sook LEE
;
Hyun Cheol CHUNG
;
Sung Hoon NOH
;
Sun Young RHA
Author Information
1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. rha7655@yuhs.ac
- Publication Type:Original Article
- Keywords:
Advanced gastric cancer;
pN3;
Prognostic factor;
Prognosis;
Survival
- MeSH:
Adenocarcinoma;
Follow-Up Studies;
Gastrectomy;
Humans;
Lymph Node Excision;
Medical Records;
Neoplasm Metastasis;
Prognosis;
Retrospective Studies;
Seeds;
Stomach Neoplasms;
Survival Rate
- From:Cancer Research and Treatment
2009;41(2):73-79
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: The aim of this study was to determine the prognosis of pN3 stage gastric cancer patients after they have undergone curative resection, and we also wanted to identify the prognostic factors according to the clinico-pathologic features. MATERIALS AND METHODS: Between January 2000 and December 2004, we retrospectively reviewed the medical records of the patients with histologically confirmed pN3 stage gastric cancer. They underwent both gastrectomy and lymphadenectomy with a curative aim. We categorized the pN3 stage patients into 2 groups; one with pN3 only (pN3M0) and the other with pN3 combined with M1 stage (pN3M1) that included peritoneal seeding, hepatic metastasis or para-aortic LN metastasis. RESULTS: Out of 467 patients with stage IV gastric adenocarcinoma who received surgery, 260 patients underwent curative resection and they were pathologically staged as N3. Among these 260 patients, 78 patients were classified as the pN3/M1 stage. For all the patients, the median follow-up period was 19 months (range: 1~108 months) and the median overall survival time was 16.2 months (95% CI, 14.1~18.3%). The 5-year survival rate of the pN3/M0 group was significantly higher than that of the pN3/M1 group (12.6% vs. 2.6%, respectively, p<0.0001). The identified predictor for a worse prognosis was an advanced T4 stage (HR: 3.38, 95% CI, 1.4~8.3, p=0.008) for the pN3 patients. CONCLUSION: The survival for the pN3 gastric cancer patients after curative gastrectomy was significantly longer in the pN3/M0 group as compared to that of the pN3/M1 group. An advanced T stage was a predictor for a poor prognosis for the pN3 patients. Therefore, diverse treatment strategies for these heterogeneous pN3 gastric cancer patients are needed for improving their survival.
